Nervewing
Bluelighter
- Joined
- Jan 5, 2016
- Messages
- 219
Hello,
If any of you are around reddit you may have seen me post about this already but I'll drop it here too
Just in the interest of exploring novel compounds, I was poking around the literature for a bit to find NDMA antagonists and then survey them for their potential psychoactive effects.
Enter CNS 5161:
CNS 5161 is a novel drug currently in the clinical trial stage for the treatment of neuropathic pain, something which other popular dissociatives have been analyzed for. It's feasibility seems to be hindered due to the reported side effects, which include dysaesthesia, numbness, lightheadedness, derealization, drowsiness, dizziness and visual disturbances. A pretty familiar array of effects, correct? The drug was administered at pretty low doses however, and all of these effects were described as mild.
So this leaves me curious as to what a dose beyond the therapeutic range may yield. Could full on dissociative effects be expected? Could they just manifest as "mild" like described in the paper and only the negative somatic effects increase with dose? Idk, I don't know much about pharmacology so its hard to say. Perhaps the folks here will have something to contribute.
The most worrisome side effect described is "Prominent cardiovascular effects were seen at doses of 1 mg and above. A 15–20% increase in mean arterial pressure was apparent", which I was informed is a pretty substantial and dangerous increase in blood pressure. Does this entirely preclude it's potential as a dissociative?
sources:
http://onlinelibrary.wiley.com/doi/10.1002/jlcr.1033/abstract
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874317/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000615/
my full write up on it (though I really put all the important information here):
http://nervewing.blogspot.com/2016/04/new-frontiers-cns-5161.html
If any of you are around reddit you may have seen me post about this already but I'll drop it here too
Just in the interest of exploring novel compounds, I was poking around the literature for a bit to find NDMA antagonists and then survey them for their potential psychoactive effects.
Enter CNS 5161:
CNS 5161 is a novel drug currently in the clinical trial stage for the treatment of neuropathic pain, something which other popular dissociatives have been analyzed for. It's feasibility seems to be hindered due to the reported side effects, which include dysaesthesia, numbness, lightheadedness, derealization, drowsiness, dizziness and visual disturbances. A pretty familiar array of effects, correct? The drug was administered at pretty low doses however, and all of these effects were described as mild.
So this leaves me curious as to what a dose beyond the therapeutic range may yield. Could full on dissociative effects be expected? Could they just manifest as "mild" like described in the paper and only the negative somatic effects increase with dose? Idk, I don't know much about pharmacology so its hard to say. Perhaps the folks here will have something to contribute.
The most worrisome side effect described is "Prominent cardiovascular effects were seen at doses of 1 mg and above. A 15–20% increase in mean arterial pressure was apparent", which I was informed is a pretty substantial and dangerous increase in blood pressure. Does this entirely preclude it's potential as a dissociative?
sources:
http://onlinelibrary.wiley.com/doi/10.1002/jlcr.1033/abstract
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874317/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000615/
my full write up on it (though I really put all the important information here):
http://nervewing.blogspot.com/2016/04/new-frontiers-cns-5161.html